GIP/GLP-1 receptor agonist (dual agonist)

Mounjaro Side Effects: Complete Guide

Mounjaro is the brand name for tirzepatide, FDA-approved for type 2 diabetes. It is the first dual GIP/GLP-1 receptor agonist, offering potentially greater weight loss than GLP-1-only medications.

Dosage Information

Forms:

injection (weekly)

Common dosages:

  • 2.5 mg weekly (starting)
  • 5 mg weekly
  • 7.5 mg weekly
  • 10 mg weekly
  • 12.5 mg weekly
  • 15 mg weekly (maximum)

Side Effects Overview

Mounjaro can cause a range of side effects. Most are mild to moderate and improve as your body adjusts to the medication. Below is a complete list organized by severity.

Severe (Seek Medical Attention)

Gallbladder Problems and Gallstones

Affects 1-3% of users — uncommon but serious

Moderate (Manageable with Strategies)

Constipation and Digestive Slowdown

Affects 60-70% of users at some point during treatment

Fatigue and Low Energy

Affects 15-30% of users, particularly in the first 1-3 months

Vomiting and Severe Nausea

Affects 5-15% of users, more common with higher doses

Mild (Common, Usually Temporary)

Nausea and Upset Stomach

Affects 20-44% of users, especially during the first few weeks or after dose increases

Sleep Issues and Insomnia

Affects 10-20% of users

Headaches

Affects 10-20% of users, especially in the first few weeks

Diarrhea and Loose Stools

Affects 10-20% of users

Bloating and Abdominal Discomfort

Affects 10-20% of users

Important Note

This information is for educational purposes only and does not replace professional medical advice. Always consult your healthcare provider about side effects and treatment decisions. If you experience severe symptoms, seek immediate medical attention.